Hypothermia Enhanced by Magnesium Sulphate
NCT02499393 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2015-07-16
Summary
New 2010 neonatal resuscitation guidelines state that offering therapeutic hypothermia (TH) should be a standard of care in managing neonates with perinatal hypoxic - ischemic insult and present with signs of moderate and/or severe hypoxic - ischemic encephalopathy (HIE) . Despite the evidence from several randomized control trial (RCT) proving its effectiveness, its effect is perceived insufficient or only modest. Thus today's research efforts are directed toward finding the new possibilities of enhancing the effects of hypothermia. List of agents with potential neuroprotective properties includes: erythropoetin, melatonin, topiramate, morphine, xenon, MgSO4. Given investigators previous experiences with preterm neonates exposed to MgSO4 prenatally or administered this drug after birth because of perinatal asphyxia, the investigators designed the trial which would evaluate the possibility of increasing the TH effect by combining this method with MgSO4. Until now there are several published studies evaluating the effectiveness of MgSO4 in the group of asphyxiated neonates, including one RCT. However, all of these studies were conducted before the era of TH Furthermore, irrespective of the potential benefits, safety of using MgSO4 during TH in the group of term neonates was not studied. It is particularly important in the light of the results presented by Mittendorf et.al. They studied the effects of prenatal aggressive treatment with MgSO4 on the outcome of preterm neonates showed that patients exposed to high doses of MgSO4 were at higher risk of severe intracranial bleeding. Other side effects of high serum magnesium levels are: vasodilatation, hypotension, cardiac arrhythmias, coagulopathy, and gastrointestinal disturbances. MgSO4 is a very attractive neuroprotective option,also because of its easy availability. Drug can be administered in the birth hospital while neonate is being prepared for the transport to TH center. Timing of the intervention is very important for neonates suffering from perinatal asphyxia. Both TH and administration of potentially neuroprotective drug should be started during "therapeutic window". It is the initial potentially reversible phase of hypoxic insult lasting about 6 hours. If the long-term follow up shows that MgSO4 has an additive neuroprotective effect and no significant side effects in the group of asphyxiated neonates treated with TH this relatively simple and not expensive intervention may be introduced into clinical practice
Conditions
- Perinatal Anoxic-ischemic Brain Injury
Interventions
- DRUG
-
Magnesium Sulfate
intravenous infusion of magnesium sulphate
Sponsors & Collaborators
-
Poznan University of Medical Sciences
collaborator OTHER -
Polish Mother Memorial Hospital Research Institute
lead OTHER
Principal Investigators
-
Ewa Gulczynska, MD PhD · Polish Mother Memorial Hospital Research Instutute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 1 Hour
- Max Age
- 6 Hours
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-04-30
- Primary Completion
- 2013-04-30
- Completion
- 2014-12-31
Countries
- Poland
Study Locations
More Related Trials
-
Systemic Hypothermia Improves Outcome of Hypoxic-Ischemic Encephalopathy
NCT00817401 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)
NCT05581927 ·Status: WITHDRAWN ·Phase: NA
-
Cooling in Mild Encephalopathy
NCT05889507 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy
NCT00890409 ·Status: COMPLETED ·Phase: PHASE3
-
Optimising Newborn Nutrition During Therapeutic Hypothermia.
NCT03278847 ·Status: COMPLETED
-
Hypothermia Therapy in Pediatric Cardiac Intensive Care Unit for Suspected for Brain Injury
NCT02395276 ·Status: UNKNOWN ·Phase: NA
-
Mesenchymal Stem Cells With Cooling Therapy for Infants With Hypoxic-Ischemic Encephalopathy
NCT07018739 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Becoming Children With Perinatal Anoxo-Ischemic Encephalopathy Without Indication of Therapeutic Hypothermia
NCT03744481 ·Status: COMPLETED
-
Hypothermia During ECMO to Decrease Brain Injury
NCT01675388 ·Status: WITHDRAWN ·Phase: NA
-
Continuous Versus Bolus Feeding in Neonates With Hypoxic Ischemic Encephalopathy
NCT06447155 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells
NCT02881970 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Cool Prime Comparative Effectiveness Study for Mild HIE
NCT04621279 ·Status: RECRUITING
-
Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia
NCT02621944 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth
NCT02071394 ·Status: COMPLETED ·Phase: PHASE2
-
Neonatal Hypoxic Ischemic Encephalopathy:Early Diagnosis and Management of Comorbidities
NCT03550612 ·Status: UNKNOWN
-
Amnioinfusion for Intrauterine Neuroprotection
NCT05513690 ·Status: UNKNOWN ·Phase: NA
-
Does Placenta Pathology Predict Outcome of Neonates With Hypoxic Ischemic Encephalopathy?"
NCT03284528 ·Status: COMPLETED
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
NCT05853601 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
MRI Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy(HIE)
NCT01128673 ·Status: WITHDRAWN
-
MRI of Neonate With HIE Before and During the Moderate Hypothermia
NCT03079492 ·Status: UNKNOWN
-
Effect of Intravenous Fluid Supplementation on Serum Bilirubin and Cardiorespiratory Parameters in Preterm Infants During Phototherapy
NCT01550627 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome
NCT03162653 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)
NCT02349672 ·Status: COMPLETED
-
The Ability of NIRS to Predict Brain Injury in Hypoxic Ischemic Encephalopathy
NCT03835039 ·Status: TERMINATED
-
Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy
NCT03163589 ·Status: UNKNOWN ·Phase: PHASE3